Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.
J Clin Oncol. 2010.
PMID: 20733132
Clinical Trial.
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
du Bois A, et al. Among authors: staehle a.
Gynecol Oncol. 2005 Feb;96(2):444-51. doi: 10.1016/j.ygyno.2004.10.020.
Gynecol Oncol. 2005.
PMID: 15661234
Clinical Trial.
Item in Clipboard
Non-enrolment of ovarian cancer patients in clinical trials: reasons and background.
Harter P, du Bois A, Schade-Brittinger C, Burges A, Wollschlaeger K, Gropp M, Schmalfeldt B, Huober J, Staehle A, Pfisterer J.
Harter P, et al. Among authors: staehle a.
Ann Oncol. 2005 Nov;16(11):1801-5. doi: 10.1093/annonc/mdi367. Epub 2005 Aug 9.
Ann Oncol. 2005.
PMID: 16091427
Free article.
Item in Clipboard
Pegylated liposomal doxorubicin and carboplatin in advanced gynecologic tumors: a prospective phase I/II study of the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR).
du Bois A, Burges A, Meier W, Pfisterer J, Schmalfeldt B, Richter B, Jackisch C, Staehle A, Kimmig R, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom.
du Bois A, et al. Among authors: staehle a.
Ann Oncol. 2006 Jan;17(1):93-6. doi: 10.1093/annonc/mdj032. Epub 2005 Nov 9.
Ann Oncol. 2006.
PMID: 16282248
Free article.
Clinical Trial.
Item in Clipboard
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials.
Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, du Bois A.
Mahner S, et al. Among authors: staehle a.
Eur J Cancer. 2013 Jan;49(1):142-9. doi: 10.1016/j.ejca.2012.07.023. Epub 2012 Aug 23.
Eur J Cancer. 2013.
PMID: 22921185
Item in Clipboard
The histone demethylase JMJD2C constitutes a novel NFE2 target gene that is required for the survival of JAK2V617F mutated cells.
Staehle AM, Peeken JC, Vladimirov G, Hoeness ME, Bojtine Kovacs S, Karantzelis N, Gruender A, Koellerer C, Jutzi JS, Pahl HL, Staehle HF.
Staehle AM, et al.
Leukemia. 2023 Apr;37(4):919-923. doi: 10.1038/s41375-023-01826-y. Epub 2023 Jan 28.
Leukemia. 2023.
PMID: 36709354
Free PMC article.
Item in Clipboard
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators.
Oza AM, et al.
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
Lancet Oncol. 2015.
PMID: 26115797
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite